CD274 and neoplasm: The enhanced effect of PD-1/PD-L1 blockade is attributed to CTLA-4 inhibition by Ipilimumab, which lead to a marked diversification of the peripheral TCR repertoire and increased infiltration of T cells into tumor tissue (174).